The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Publication

Antiviral Research

Author(s)

Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff

Abstract

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Date

April 3, 2020

View study